In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum

Cancer Letters

Volumn 134, Issue 1, 1998, Pages 111-118

  Ohta, Hiroho ^a   Sakamoto, Hideki ^a   Satoh, Kazuo ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endometrial cancer; Gonadotropin releasing hormone agonist; Human telomerase; Ovarian cancer

Indexed keywords

BUSERELIN; CISPLATIN; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BUSERELIN; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 0032433402     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00270-5     Document Type: Article

References (19)

1. Emons G., Schally A.V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum. Reprod. 9:(7):1994;1364-1379.
2. Irmer G., Büger C., Ortmann O., Schulz K.-D., Emons G. Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. 79:(3):1994;916-919.
3. Emons G., Schröer B., Ortmann O., Westphalen S., Schulz K.-D., Schally A.V. High affinity binding and direct antiproliferative effects of luteinizing hormone releasing hormone analogs in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. 77:(6):1993;1458-1464.
4. Chi L., Zhou W., Prikhozhan A., Flanagan C., Davidson J.S., Golembo M., Illing N., Millar R.P., Sealfon S.C. Cloning and characterization of the human GnRH receptor. Mol. Cell. Endocrinol. 91:1993;R1-R5.
5. Kakar S.S., Musgrove L.C., Devor D.C., Sellers J.C., Neill J.D. Cloning, sequencing and expression of human gonadotropin-releasing hormone (GnRH) receptor. Biochem. Biophys. Res. Commun. 189:1992;289-295.
6. Imai A., Ohno T., Iida K., Fuseya T., Furui T., Tamaya T. Gonadotropin-releasing hormone receptor in gynecologic tumors. Cancer. 74:1994;2555-2561.
7. Eidne K.A., Flanagan C.A., Millar R.P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science. 229:1985;989-991.
8. Miller W.R., Scott W.N., Morris R., Fraser H.M., Sharpe R.M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 313:1985;231-233.
9. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:(23):1994;2011-2015.
10. Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet. Gynaecol. Jpn. 37:(7):1985;1103-1111.
11. Sakamoto H., Deng X., Shirakawa T., Ige S., Ohtani K., Saitoh A., Takami M., Takami T., Satoh K. Establishment of metastatic sub-clone from estrogen independent Ishikawa cells and its characterization in vitro and in vivo. Acta Obstet. Gynaecol. Jpn. 47:(3):1995;249-256.
12. Feng J., Funk W.D., Wang S.-S., Weinrich S.L., Avilion A.A., Chiu C.-P., Adams R.R., Chang E., Allsopp R.C., Yu J., Le S., West M.D., Harley C.B., Andrews W.H., Greider C.W., Villeponteau B. The RNA component of human telomerase. Science. 269:1995;1236-1241.
13. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-251.
14. Stojilkovic S.S., Reinhart J., Catt K.J. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr. Rev. 15:1994;462-499.
15. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 80:1995;225-236.
16. Ron I.G., Wigler N., Merimsky O., Inbar M.J., Chaitchik S. A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest. 13:(3):1995;272-275.
17. Emons G., Ortmann O., Teichert H.M., Fassl H., Lohrs U., Kullander S., Kauppila A., Ayalon D., Schally A., Oberheuser F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer. 78:(7):1996;1452-1460.
18. van der Vange N., Greggi S., Burger C.W., Kenemans P., Vermorken J.B. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol. 34:(6):1995;813-820.
19. Burger C.W., Prinssen H.M., Kenemans P. LHRH agonist treatment of breast cancer and gynecological malignancies: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 67:(1):1996;27-33.